by ltsiwpadmin | Jun 5, 2017 | News
Can-Fite BioPharma Ltd. June 5, 2017 PETACH TIKVA, Israel, June 5, 2017 /PRNewswire/ — Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory...
by ltsiwpadmin | Jun 5, 2017 | News
Published: June 5, 2017 Boston—Serum microRNA signatures have the potential to identify patients with non-alcoholic steatohepatitis who need treatment for the condition, researchers have found. The discovery, if confirmed, would be welcome news given that rates of...
by ltsiwpadmin | May 29, 2017 | News
Medical News Bulletin May 29, 2017 Fatty liver disease commonly affects alcoholics and those who are overweight or diabetic. There are currently no treatments for this disease, aside from recommendations to exercise and make lifestyle changes. A recent review article...
by ltsiwpadmin | May 26, 2017 | News
Source: The Life Sciences Report May 26, 2017 (Investorideas.com Newswire) NASH is an epidemic in the U.S., with more than 100 million people believed to be affected. Yet no FDA-approved treatments are available, with the exception of liver transplantation for...
by ltsiwpadmin | May 18, 2017 | News
Daniela Semedo, PhD May 18, 2017 Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver diseases such as nonalcoholic steatohepatitis (NASH). Boston-based Albireo has reported...
by ltsiwpadmin | May 16, 2017 | News
Source: Children’s Hospital Los Angeles Summary A team of investigators has identified key inflammatory cells involved in nonalcoholic fatty liver disease. Current treatment for the disorder involves changes to diet, yet no medication has been approved for...
Recent Comments